The global AI in endoscopy market size 2026 was valued at USD 2.02 billion in 2025 and is projected to grow from USD 2.35 billion in 2026 to USD 14.86 billion by 2034, reflecting a robust CAGR of 25.92% over the forecast period.
AI in endoscopy applies machine learning, deep learning-based computer vision, and natural language processing to analyze endoscopy video and procedural data in real time. It supports clinicians in lesion and polyp identification (CADe), optical characterization (CADx), and procedural quality assurance through tools such as bowel-prep evaluation, coverage reminders, and automated documentation.
Key Market Drivers
- Rising colorectal cancer (CRC) screening volumes are driving demand for consistent, scalable polyp detection tools. AI-driven CADe systems address variability among endoscopists and help reduce adenoma miss rates across high-volume programs.
- Growing OEM and AI vendor investment is accelerating the commercialization of validated, regulatory-cleared products, making AI adoption smoother across hospitals and ambulatory surgery centers (ASCs).
- Integration with existing platforms via cloud and edge deployment is reducing IT friction, enabling fast software updates and fleet-wide rollouts without replacing existing equipment.
Key Restraints & Challenges
- Regulatory complexity across regions and inconsistent reimbursement pathways delay product launches and raise compliance costs, particularly as AI models undergo frequent updates.
- High implementation costs remain a barrier, especially for smaller hospitals with lean IT teams, increasing total cost of ownership and slowing procurement approvals.
Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/ai-in-endoscopy-market-115731
Segmentation Highlights
By Component
- Hardware/Devices holds the largest share, driven by hospitals' preference for turnkey, validated devices that integrate with existing endoscopy towers.
- Software & Services is the fastest-growing segment, expected to rise at a CAGR of 29.46%.
By Deployment
- On-premise leads with ~49.6% share in 2026, as hospitals prioritize keeping video data within their own networks for governance and cybersecurity.
- Cloud-based is the fastest-growing deployment mode, projected at a CAGR of 39.64%.
By Technology
- Machine Learning & Deep Learning dominates with ~74.9% share in 2026, owing to superior real-time computer vision performance across high-frame-rate endoscopy feeds.
- Natural Language Processing is set to grow at 35.78% CAGR.
By Type
- CADe (Computer-Aided Detection) holds ~68.6% share in 2026, as it functions as a real-time second observer without disrupting clinical decision workflows.
- CADx (Computer-Aided Diagnosis) is growing at 33.67% CAGR.
By Application
- Gastrointestinal Endoscopy dominates with ~80.2% share in 2026, benefiting from the largest and most standardized procedure base, particularly colonoscopy.
- Urological Endoscopy is expected to grow at a CAGR of 34.45%.
By End User
- Hospitals & ASCs lead with ~69.0% share in 2026, given high procedure volumes and stronger ROI from AI adoption at scale.
- Specialty Clinics are projected to grow at 30.61% during the forecast period.
Regional Outlook
North America leads globally, with the U.S. alone estimated at ~USD 0.93 billion in 2026, representing roughly 39.7% of the global market.
Competitive Landscape
The market is moderately fragmented, with large OEMs competing alongside specialist AI software vendors. Key players include:
- Medtronic – GI Genius platform; secured a 3-year U.S. VA contract for ~100 units (Nov 2024)
- Olympus Corporation – Launched OLYSENSE with CADDIE CADe solution commercially in the U.S. (Sep 2025)
- FUJIFILM Holdings – Received FDA 510(k) clearance for CAD EYE integrated AI detection system (Mar 2024)
- PENTAX Medical – Active in endoscopy training and innovation partnerships
- Iterative Health – SKOUT system received FDA clearance (May 2025); deploying across California ASCs
- Others: AI Medical Service Inc., Wision A.I., Body Vision Medical, MAGENTIQ EYE
Recent Industry Developments
- Feb 2026: Olympus EAGLE trial results confirmed CADDIE aids detection of hard-to-detect colorectal lesions.
- Jul 2025: Olympus partnered with Revival Healthcare Capital to co-found Swan EndoSurgical for GI robotics.
- Jan 2025: Iterative Health announced SKOUT deployment across Unio Specialty Care's California ASCs.
- Oct 2024: GI Alliance partnered with Medtronic to deploy GI Genius across 400+ sites.